Overall Status

Active, not recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

M.D. Anderson Cancer Center (1)

Southwest Oncology Group (1)

Collaborator

Janssen Pharmaceuticals (1)

National Cancer Institute (NCI) (1)

Takeda (1)

Intervention

daratumumab (1)

dexamethasone (1)

isatuximab (1)

ixazomib (1)

laboratory biomarker analysis (1)

Study Documents

Intervention Type

biological (2)

drug (1)

other (1)

Funder Type

Other (2)

Study Type

Interventional (2)

refractory primary amyloidosis

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea Trial in United States (Isatuximab, Laboratory Biomarker

Active, not recruiting

Amorphous, Eosinophilic, and Acellular Deposit
+12 more

Isatuximab
Laboratory Biomarker Analysis

Anchorage, Alaska
+344 more

Aug 22, 2022

Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis Trial in Houston

Recruiting

Newly Diagnosed Primary Amyloidosis
+2 more

Daratumumab
+2 more

Houston, Texas

M D Anderson Cancer Center

Feb 12, 2021